A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

NCT06241118 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

636

Enrollment

INDUSTRY

Sponsor class

Conditions

Dermatitis Atopic

Interventions

DRUG: Amlitelimab
DRUG: Placebo
DRUG: Topical corticosteroids
DRUG: Topical tacrolimus or pimecrolimus

Sponsor

Sanofi